+Compare
AEZS
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
13.1M

AEZS Aeterna Zentaris Forecast, Technical & Fundamental Analysis

a developer of pharmaceutical products

Industry Biotechnology
GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for AEZS with price predictions
08:00 PM EDT Jun 01, 2023

Momentum Indicator for AEZS turns negative, indicating new downward trend

AEZS saw its Momentum Indicator move below the 0 level on June 02, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In of the 82 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for AEZS moved out of overbought territory on April 27, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for AEZS turned negative on May 11, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

AEZS moved below its 50-day moving average on May 26, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEZS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AEZS entered a downward trend on May 26, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AEZS advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.428) is normal, around the industry mean (25.045). P/E Ratio (0.000) is within average values for comparable stocks, (123.096). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.331). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (2.136) is also within normal values, averaging (307.081).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AEZS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEZS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.11B. The market cap for tickers in the group ranges from 365 to 353.84B. NONOF holds the highest valuation in this group at 353.84B. The lowest valued company is CLAZF at 365.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 40%, and the average quarterly price growth was 52%. EFTR experienced the highest price growth at 77%, while BLCM experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -2%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 54
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

AEZS is expected to report earnings to fall 2.27% to -86 cents per share on August 10

Aeterna Zentaris AEZS Stock Earnings Reports
Q2'23
Est.
$-0.86
Q1'23
Beat
by $0.05
Q4'22
Missed
by $1.63
Q3'22
Missed
by $0.02
Q2'22
Missed
by $0.84
The last earnings report on May 09 showed earnings per share of -87 cents, beating the estimate of -93 cents. With 57.26K shares outstanding, the current market capitalization sits at 13.10M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
222 Bay Street
Phone
N/A
Employees
21
Web
https://www.zentaris.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CING1.080.17
+18.92%
Cingulate
SYF33.041.49
+4.72%
Synchrony Financial
SGC8.730.36
+4.30%
Superior Group of Companies
LASR14.330.30
+2.14%
nLIGHT
AVAV98.841.24
+1.27%
AeroVironment

AEZS and

Correlation & Price change

A.I.dvisor tells us that AEZS and CMRX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AEZS and CMRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AEZS
1D Price
Change %
AEZS100%
-1.11%
CMRX - AEZS
31%
Poorly correlated
+4.32%
ENVB - AEZS
30%
Poorly correlated
-11.04%
CUE - AEZS
29%
Poorly correlated
+1.23%
AADI - AEZS
27%
Poorly correlated
+2.03%
FATE - AEZS
27%
Poorly correlated
+3.55%
More

Groups containing AEZS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AEZS
1D Price
Change %
AEZS100%
-1.11%
drugs
(undefined stocks)
26%
Poorly correlated
+1.62%
biotechnology
(undefined stocks)
24%
Poorly correlated
+1.52%
pharmaceuticals
(undefined stocks)
21%
Poorly correlated
+1.61%